U.S. License Holder:
Celltrion USA
Date of License:
October-20-2023
Last Update:
Sep-30-2024
FDA-Approved Indications
ZYMFENTRA (infliximab-dyyb for subcutanous use) is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of:
Moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously;
Moderately to severely active Crohn's disease following treatment with an infliximab product administered intravenously.